FORM 6 - K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of October 2000
Commission File Number 0-29350
VASOGEN INC.
(Translation of Registrant's name into English)
2155 Dunwin Drive, Suite 10, Mississauga, Ontario, L5L 4M1
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20 - F or Form 40 - F.)
Form 20 - F [X] Form 40 - F
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes ______ No [X]
This Form 6-K consists of:
A press release issued by Vasogen Inc. on October 3, 2000, entitled:
"Vasogen Results Selected for Presentation at American Heart Association
Meeting".
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VASOGEN INC.
By: /s/ Christopher Waddick
-----------------------------
(Name: Christopher Waddick)
(Title: Vice-President, Finance & CFO)
Date: October 3, 2000
<PAGE>
Vasogen Inc.
INVESTOR CONTACT
2155 Dunwin Drive
Mississauga, ON, Canada L5L 4M1 Glenn Neumann
tel: (905) 569-2265 fax: (905) 569-9231 Investor Relations
www.vasogen.com (905) 569-9065
[email protected]
--------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
Vasogen Results Selected for Presentation at
American Heart Association Meeting
Toronto, Ontario (October 3, 2000) -- Vasogen Inc. (TSE:VAS; AMEX:MEW) today
announced that previously reported research results concerning the therapeutic
benefits of its immune modulation therapy, VasoCare(TM), have been selected for
presentation at the 73rd Scientific Sessions of the American Heart Association
(AHA) in New Orleans, November 12 - 15, 2000. Data is to be presented from both
pre-clinical research in atherosclerosis, conducted by Dr. David Courtman of St.
Michael's Hospital, University of Toronto, and from a clinical trial conducted
by Dr. Lars Edvinsson of the University of Lund, Sweden, involving patients
suffering from peripheral vascular disease. These results demonstrate the
ability of VasoCare(TM) therapy to significantly improve blood vessel function.
Impaired blood vessel function is recognized as a significant contributor to the
progression of atherosclerosis ("hardening of the arteries"), which is the major
underlying cause of heart attack, stroke, peripheral vascular disease, and other
cardiovascular diseases. The AHA lists cardiovascular disease as the leading
cause of death in the United States.
"The ability to regulate immune responses to significantly improve blood vessel
function underscores the potential for VasoCare(TM) therapy to become an
important new approach to the treatment of atherosclerosis and a number of
related diseases," commented Dr. Courtman.
The AHA's Scientific Sessions, with the goal of improving the care of
cardiovascular patients, is noted as the premier annual meeting in the world
devoted to cardiovascular research and medicine. Approximately 35,000
individuals including cardiologists, internists, researchers, family
practitioners, surgeons, and nurses are expected to attend the meeting.
Vasogen expects to report on a double-blind placebo-controlled clinical trial of
patients with peripheral vascular disease, a condition associated with poor
blood vessel function and atherosclerosis, prior to year-end. Over the next
three quarters, the Company also expects to report results from a number of
additional clinical trials targeting the treatment and prevention of psoriasis,
congestive heart failure, ischemia/reperfusion injury, and graft-versus-host
disease.
Vasogen is focused on developing immune modulation therapies to
advance the treatment of cardiovascular, autoimmune and related inflammatory
diseases. These therapies are designed to target fundamental disease-causing
events, providing safe, effective treatment.
Statements contained in this press release, including those pertaining to
scientific and clinical research, commercialization plans, strategic
alliances, and intellectual property protection, other than statements of
historical fact, are forward-looking statements subject to a number of
uncertainties that could cause actual results to differ materially from
statements made.
